Shearer M H, Lanford R L, Kennedy R C
Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, TX 78228-0147.
J Immunol. 1990 Aug 1;145(3):932-9.
Mouse monoclonal anti-Id antibodies were generated against a mouse mAb (Ab-1) preparation specific for SV40 large tumor Ag (T-Ag). Four monoclonal anti-Id preparations each inhibited the binding of the monoclonal anti-SV40 T-Ag Ab-1 preparation to SV40 T-Ag. These anti-Id preparations appeared to recognize similar idiotopes on the monoclonal anti-SV40 T-Ag Ab-1 based on competitive cross-inhibition studies. One of these anti-Id preparations, designated 57B, was examined further for its in vivo modulatory capacity in mice. This anti-Id induced an Ab-3 response in BALB/c mice that recognized SV40 T-Ag (Ag+) and expressed an Id that was shared by the monoclonal anti-SV40 T-Ag Ab-1 preparation (Id+). The Id expressed on the Ab-3 differed from the Id induced in BALB/c mice immunized with the nominal SV40 T-Ag. Furthermore, characterization of the humoral immune response induced by anti-Id immunization indicated that the Ab-3 also recognized different epitopes on SV40 T-Ag when compared to the anti-SV40 T-Ag Ab-1 preparation used to generate the anti-Id. These studies indicate that monoclonal anti-Id can be used to induce humoral immune responses to a viral encoded tumor-associated Ag in vivo with 1) and Id specificity that differs from that expressed on antibodies produced by immunization with the nominal Ag and 2) an epitope specificity distinct from the Ab-1 preparation used for the production of the anti-Id.
针对一种对SV40大肿瘤抗原(T抗原)具有特异性的小鼠单克隆抗体(Ab-1)制剂,制备了小鼠单克隆抗独特型抗体。四种单克隆抗独特型制剂均抑制了抗SV40 T抗原单克隆抗体Ab-1制剂与SV40 T抗原的结合。基于竞争性交叉抑制研究,这些抗独特型制剂似乎识别抗SV40 T抗原单克隆抗体Ab-1上的相似独特位。其中一种抗独特型制剂,命名为57B,进一步检测了其在小鼠体内的调节能力。这种抗独特型抗体在BALB/c小鼠中诱导了一种抗-3反应,该反应识别SV40 T抗原(Ag+)并表达一种与抗SV40 T抗原单克隆抗体Ab-1制剂共有的独特型(Id+)。抗-3上表达的独特型不同于用名义上的SV40 T抗原免疫的BALB/c小鼠中诱导的独特型。此外,抗独特型免疫诱导的体液免疫反应的特征表明,与用于产生抗独特型的抗SV40 T抗原Ab-1制剂相比,抗-3也识别SV40 T抗原上的不同表位。这些研究表明,单克隆抗独特型抗体可用于在体内诱导针对病毒编码的肿瘤相关抗原的体液免疫反应,其具有1)与用名义抗原免疫产生的抗体所表达的独特型特异性不同的独特型特异性,以及2)与用于产生抗独特型的Ab-1制剂不同的表位特异性。